NCT02412436View on ClinicalTrials.gov

PK Study of Rifampicin Interactions With DMPA and Efavirenz in TB

PHASE2CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

November 3, 2015

Primary Completion Date

June 15, 2017

Study Completion Date

June 15, 2017

Conditions
HIV-1 InfectionTuberculosis
Interventions
DRUG

Depot medroxyprogesterone acetate

Depot medroxyprogesterone acetate intramuscular injection

Trial Locations (5)

40100

Kenya Medical Research Institute/Center for Disease Control (KEMRI/CDC) CRS (31460), Kisumu

Unknown

Gaborone Prevention/Treatment Trials CRS (12701), Gaborone

Univ. of Witwatersrand CRS (11101), Johannesburg

UZ-Parirenyatwa CRS (30313), Harare

4013 SF

Durban Adult HIV CRS (11201), Durban

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

NETWORK

NCT02412436 - PK Study of Rifampicin Interactions With DMPA and Efavirenz in TB | Biotech Hunter | Biotech Hunter